Juno Therapeutics has acquired 4 companies of its own.
Juno Therapeutics’ largest acquisition to date was in 2016, when it acquired AbVitro for $78M. Juno Therapeutics has acquired in 1 US state, and 2 countries. The Company’s most targeted sectors include life science (75%) and information technology (25%).
307 Westlake Avenue North, Suite 300,
Seattle, Washington
98109
United States,
(206) 582-1600
www.junotherapeutics.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2016-07-14 |
RedoxTherapies, Inc. · Life Science
Boston, Massachusetts RedoxTherapies, Inc. is an adenosine research company. Redox is to utilize A2 adenosine antagonists to re-activate the otherwise inhibited tumor-reactive T cells, which remain inhibited even after blockade of immunological checkpoint inhibitors. |
10 | Add-on Acquisition | - |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
